A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Key Inclusion Criteria:

• Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)

• Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment

• Measurable disease by imaging

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

• Life expectancy ≥ 6 months

• Adequate bone marrow function

• Adequate renal and hepatic function

Key Exclusion Criteria:

• Previous systemic treatment for CLL/SLL

• Requires ongoing need for corticosteroid treatment

• Known prolymphocytic leukemia or history of or suspected Richter's transformation.

• Clinically significant cardiovascular disease

• Prior malignancy within the past 3 years, except for curatively treated basal orsquamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ ofthe cervix of breast, or localized Gleason score 6 prostate cancer

• History of severe bleeding disorder

• History of stroke or intracranial hemorrhage within 6 months before the first doseof study drug

• Severe or debilitating pulmonary disease

• Inability to swallow capsules or disease affecting gastrointestinal function

• Active infection requiring systemic treatment

• Known central nervous system involvement by leukemia or lymphoma

• Underlying medical condition that will render the administration of study drughazardous or obscure interpretation of toxicity or AEs

• Known infection with human immunodeficiency virus (HIV) or active hepatitis B or Cinfection

• Major surgery ≤ 4 weeks prior to start of study treatment

• Pregnant or nursing females

• Vaccination with live vaccine within 35 days prior to the first dose of study drug.

• Ongoing alcohol or drug addiction

• Known hypersensitivity to zanubrutinib, bendamustine, rituximab, or venetoclax (asapplicable) or any other ingredients of the study drugs

• Requires ongoing treatment with strong cytochrome P450 (CYP3A) inhibitor or inducer

• Concurrent participation in another therapeutic clinical study

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.